ERBB2 and gastric cancer: Several therapeutic agents have received FDA approval specifically for treating gastric cancer, including trastuzumab for HER2-positive tumors; the antiangiogenic agent ramucirumab; and immune checkpoint inhibitors such as nivolumab, pembrolizumab, and sintilimab [1,[3], [4], [5]].